Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Warner Bros
WBD
|
+$130M |
| 2 |
Tesla
TSLA
|
+$76.4M |
| 3 |
Roblox
RBLX
|
+$50.1M |
| 4 |
VICI Properties
VICI
|
+$43.2M |
| 5 |
Danaher
DHR
|
+$41.2M |
Top Sells
| 1 |
AT&T
T
|
+$209M |
| 2 |
CERN
Cerner Corp
CERN
|
+$119M |
| 3 |
Baidu
BIDU
|
+$91.9M |
| 4 |
Canadian National Railway
CNI
|
+$53.8M |
| 5 |
Meta Platforms (Facebook)
META
|
+$37.5M |
Sector Composition
| 1 | Technology | 26.45% |
| 2 | Healthcare | 15.87% |
| 3 | Consumer Discretionary | 11.68% |
| 4 | Communication Services | 8.96% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Monte Rosa Therapeutics
GLUE
$298M
| $425K | ﹤0.01% |
43,900
+16,400
| +60% | +$159K |
|
2652
Viridian Therapeutics
VRDN
$1.65B
| $425K | ﹤0.01% |
+36,700
| New | +$425K |
|
2653
Intapp
INTA
$3.72B
| $423K | ﹤0.01% |
28,900
| – | – |
|
2654
Dyne Therapeutics
DYN
$1.88B
| $418K | ﹤0.01% |
60,800
+5,900
| +11% | +$40.6K |
|
2655
Cambium Networks
CMBM
$18.8M
| $416K | ﹤0.01% |
28,400
+6,300
| +29% | +$92.3K |
|
2656
Vital Farms
VITL
$2.12B
| $416K | ﹤0.01% |
47,500
+9,400
| +25% | +$82.3K |
|
|
CMAX
2657
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $411K | ﹤0.01% |
+3,773
| New | +$411K |
|
2658
McEwen Inc.
MUX
$734M
| $405K | ﹤0.01% |
92,293
| – | – |
|
|
CMRX
2659
DELISTED
Chimerix, Inc.
CMRX
| $404K | ﹤0.01% |
194,400
+19,800
| +11% | +$41.1K |
|
2660
Evolv Technologies
EVLV
$1.44B
| $403K | ﹤0.01% |
151,500
| – | – |
|
2661
Palladyne AI
PDYN
$295M
| $403K | ﹤0.01% |
+25,250
| New | +$403K |
|
2662
Vivid Seats
SEAT
$105M
| $402K | ﹤0.01% |
+2,690
| New | +$402K |
|
|
BBIG
2663
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
| $401K | ﹤0.01% |
14,520
-6,920
| -32% | -$191K |
|
2664
Erasca
ERAS
$440M
| $399K | ﹤0.01% |
71,600
+14,200
| +25% | +$79.1K |
|
2665
Cullinan Oncology
CGEM
$403M
| $396K | ﹤0.01% |
30,900
-5,300
| -15% | -$67.9K |
|
|
ENFN
2666
DELISTED
Enfusion, Inc.
ENFN
| $395K | ﹤0.01% |
+38,700
| New | +$395K |
|
|
PYR
2667
DELISTED
PyroGenesis Canada Inc. Common Shares
PYR
| $392K | ﹤0.01% |
203,200
| – | – |
|
2668
Navitas Semiconductor
NVTS
$1.23B
| $391K | ﹤0.01% |
+101,300
| New | +$391K |
|
2669
Bristow Group
VTOL
$1.09B
| $391K | ﹤0.01% |
16,700
| – | – |
|
|
IGMS
2670
DELISTED
IGM Biosciences
IGMS
| $388K | ﹤0.01% |
21,500
+3,000
| +16% | +$54.1K |
|
2671
NextDecade
NEXT
$2.6B
| $387K | ﹤0.01% |
+87,200
| New | +$387K |
|
2672
Blue Bird Corp
BLBD
$1.85B
| $383K | ﹤0.01% |
41,611
| – | – |
|
2673
The Honest Company
HNST
$438M
| $378K | ﹤0.01% |
129,500
+64,900
| +100% | +$189K |
|
2674
Purple Innovation
PRPL
$115M
| $377K | ﹤0.01% |
123,300
-18,200
| -13% | -$55.6K |
|
|
DBD
2675
DELISTED
Diebold Nixdorf Incorporated
DBD
| $377K | ﹤0.01% |
166,159
-9,900
| -6% | -$22.5K |
|